(c) 2024 PillSync.com

saxagliptin 5 MG Oral Tablet Onglyza

1 INDICATIONS AND USAGE ONGLYZA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Limitations of use: • Not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [ see Clinical Studies (14) ]. 1.2 Limitations of Use ONGLYZA is not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

AstraZeneca Pharmaceuticals LP


2 years ago ROUND PINK 5 4215 saxagliptin 5 MG Oral Tablet Onglyza

ROUND PINK 5 4215

2 years ago ROUND PINK 5 4215 saxagliptin 5 MG Oral Tablet Onglyza

5 4215 ROUND PINK

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied ONGLYZA tablets have markings on both sides and are available in the strengths and packages listed in Table 16. Table 16: ONGLYZA Tablet Presentations Tablet Strength film-coated Tablet Color/Shape Tablet Markings Package Size NDC Code 5 mg pink biconvex, round “5” on one side and “4215” on the reverse, in blue ink Bottles of 30 Bottles of 90 0310-6105-30 0310-6105-90 2.5 mg pale yellow to light yellow biconvex, round “2.5” on one side and “4214” on the reverse, in blue ink Bottles of 30 Bottles of 90 0310-6100-30 0310-6100-90 Storage and Handling Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [ see USP Controlled Room Temperature].


More pills like ROUND 5 4215












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site